We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $13.5 · 4 analysts
Stored first · Google News · Yahoo Finance (English)
Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors - Stock Titan
Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors Stock Titan
Price to book forward of Journey Medical Corporation – NASDAQ:DERM - TradingView
Price to book forward of Journey Medical Corporation – NASDAQ:DERM TradingView
Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of "Hold" from Analysts MarketBeat
Journey Medical Corp focuses on dermatology growth. DERM stock reflects a specialized niche strategy - AD HOC NEWS
Journey Medical Corp focuses on dermatology growth. DERM stock reflects a specialized niche strategy AD HOC NEWS
Form 4 Journey Medical Corp For: 2 July By Investing.com - Investing.com Canada
Form 4 Journey Medical Corp For: 2 July By Investing.com Investing.com Canada
DERM Stock Price, Quote & Chart - ChartMill
DERM Stock Price, Quote & Chart ChartMill
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | — | — | — | $18.37M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.18 | — | — | $13.14M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.8 | — | — | $42.51M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.69 | — | — | $27.89M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 26. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 25. | HC Wainwright & Co. | — | Initiate coverage | — → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 14. | Lake Street | — | Maintain | Buy → Buy | — | Lake Street: Buy |
| 2025. 07. 31. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
| 2024. 02. 16. | Alliance Global Partners | — | Initiate coverage | — → Buy | — | Alliance Global Partners: Buy |
| 2023. 09. 07. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.